Neurocrine Biosciences
Pays vs peer median
×1.32
+32% premium
Sample
4
low confidence
Last refreshed
2026-04-13
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| neurology | ×1.21 | 3 |
By stage at signing
| Phase | Premium | Deals |
|---|---|---|
| preclinical | ×1.40 | 3 |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | Vykat XR | Soleno Therapeutics | hyperphagia | unknown | $2.9B | $2.9B |
| 2023 | Anti-Tau antibody transport vehicle | Voyager Therapeutics | Alzheimer's Disease, Tauopathies | preclinical | $115M | $1.7B |
| 2022 | parkinsons | Voyager Therapeutics | parkinsons | preclinical | $165M | $1.7B |
How this is computed
For each Neurocrine Biosciences deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 4 disclosed deal premiums vs. peer medians. Raw premium 1.319, clamped to [0.7, 1.5].